<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id><journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id><journal-id journal-id-type="hwp">nng</journal-id><journal-id journal-id-type="publisher-id">NNG</journal-id><journal-title-group><journal-title>Neurology: Genetics</journal-title></journal-title-group><issn pub-type="epub">2376-7839</issn><publisher><publisher-name>Wolters Kluwer</publisher-name><publisher-loc>Baltimore</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6878943</article-id><article-id pub-id-type="publisher-id">NG2019011056</article-id><article-id pub-id-type="doi">10.1212/NXG.0000000000000377</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>91</subject><subject>161</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical/Scientific Notes</subject></subj-group></article-categories><title-group><article-title>Galloping tongue syndrome in a <italic>PRRT2</italic> mutation carrier</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vilas</surname><given-names>Dolores</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Marc&#x000e9;-Grau</surname><given-names>Anna</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Macaya</surname><given-names>Alfons</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Illumina, speaker honoraria</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>European Journal of Paediatric Neurology, Editorial Board, 2018-2019</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Valls-Sol&#x000e9;</surname><given-names>Josep</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Associate Editor for Clinical Neurophysiology PracticeDeputy Editor for Brain Stimulation</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tolosa</surname><given-names>Eduard</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>honoraria as a speaker for UCB, Boeringer Ingelheim, Novartis, Abbot, Medtronic, Solvay, GSK, Teva</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial advisory board member for Journal Neurological Sciencies</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Date of filing: 17.12.2015 Title: method for the sub-classification of patients suffering from parkinson disease</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>The Michael J Fox foundation for Parkinson's Disease Novartis UCB Abbot Teva</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Parkinson's Disease and Movement Disorders Unit (D.V., E.T.), Neurology Service, ICN, Hospital Cl&#x000ed;nic, University of Barcelona, Spain; Pediatric Neurology Research Group (A.M.-G., A.M.), Vall d'Hebron Institut de Recerca (VHIR), Universitat Aut&#x000f2;noma de Barcelona, Spain; Electrophysiology Unit (J.V.-S.), Neurology Service, ICN, Hospital Clinic, University of Barcelona, Spain; Institut August Pi I Sunyer Biomedical Research Institute (IDIBAPS) (J.V.-S., E.T.).</aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Dr. Tolosa <email>etolosa@clinic.cat</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/6/e372/tab-article-info">Neurology.org/NG</ext-link> for full disclosures. Funding information is provided at the end of the article.</p></fn><fn fn-type="other"><p>The Article Processing Charge was funded by the authors.</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>11</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>5</volume><issue>6</issue><elocation-id>e377</elocation-id><history><date date-type="received"><day>28</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>09</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NG2019011056.pdf"/><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>video</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Abnormal lingual movements are not uncommon. A rare lingual syndrome consisting of involuntary wave-like lingual movements has been labeled as &#x0201c;galloping tongue.&#x0201d;<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Herein, we report a patient with galloping tongue syndrome carrier of a mutation in the <italic>PRRT2</italic> gene.</p><sec id="s1"><title>Clinical findings</title><p>A 17-year-old woman presented with involuntary tongue movements within the past years, appearing only with tongue protrusion. &#x0201c;Wavy&#x0201d; contractions of the tongue were evident during sustained tongue protrusion (<xref ref-type="supplementary-material" rid="SM1">video 1</xref>). The contractions developed immediately after sticking the tongue out, persisted during protrusion, and disappeared while at rest. The movements could not be disrupted, suppressed, or entrained with examiner-given rhythmic activities. Abrupt body movements, sleep deprivation, or coffee intake did not affect the abnormal movement. There was no history of exposure to neuroleptic medication or head trauma. The tongue contractions seemed to begin in the posterior midline region and progress in a wavy fashion to the anterior and lateral parts of the tongue. The results of routine hematologic and blood biochemistry including thyroid function tests, copper levels, and ceruloplasmin were normal. A urine toxicology screen did not reveal the presence of any drug of abuse. An electrophysiologic study with electrodes applied on the surface of the tongue showed no electrical activity while at rest. With tongue protrusion, the EMG activity was segmented in discharges of 200&#x02013;300 ms duration and separated by brief periods of silence, with an approximate frequency of 3 per second (<xref ref-type="fig" rid="F1">figure 1</xref>). Her brain MRI was normal. Because the movement disorder did not affect the patient's orolingual function, no treatment was started.</p><supplementary-material content-type="local-data" id="SM1"><object-id pub-id-type="doi">10.1212/000377_Video_1</object-id><label>Video 1</label><caption><p>17-year-old woman with tongue movements appearing only during tongue protrusion. &#x0201c;Wavy&#x0201d; contractions of the tongue are evident during sustained tongue protrusion.<inline-supplementary-material mimetype="video" mime-subtype="quicktime" xlink:href="000377_Video_1.mov" id="d35e942" content-type="local-data">Download Supplementary Video 1</inline-supplementary-material> via <ext-link ext-link-type="uri" xlink:href="10.1212/000377_Video_1">http://dx.doi.org/10.1212/000377_Video_1</ext-link></p></caption></supplementary-material><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Electromyographic activity of the tongue recorded with surface electrodes during tongue protrusion</title><p>Discharges of 200&#x02013;300 ms duration and separated by brief periods of silence, with an approximate frequency of 3 per second were observed during tongue protrusion. Broken lines have been added to underline each EMG discharge.</p></caption><graphic xlink:href="NG2019011056f1"/></fig><p>The patient's sister, a 14-year-old, presented with short episodes of choreo-dystonic movements of the left arm and neck that appeared when she started to run since the age of 10. These episodes usually last a few seconds and occur at least 10 times per day. Her consciousness level was normal during episodes. Her medical history included migraine. She was diagnosed as having paroxysmal kinesigenic dyskinesias (PKD). Treatment with carbamazepine led to a complete remission of the movements.</p><p>There was no family history of epilepsy or infantile convulsions. The patient's mother had severe recurrent migraine headaches. Her maternal cousin had been diagnosed with PKD.</p><p>The patient, her 2 sisters (1 healthy and the other affected with PKD), and their mother were available for <italic>PRRT2</italic> mutation screen (<xref ref-type="fig" rid="F2">figure 2</xref>). Direct sequencing identified a heterozygous truncating mutation in the proband, her mother, and the symptomatic sister: GRC37/hg19: chr16:29825025 GA/A, NM_145239: c.650delG, producing the amino acid change NP_660282.2: p.R217Qfs*12. This variant is not listed in public genomic databases, including ExAC (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/)">exac.broadinstitute.org/</ext-link>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title><italic>PRRT2</italic> mutational analysis in a family with paroxysmal neurologic disorder</title><p>Right, <italic>PRRT2</italic> electropherograms: Top, wildtype sequence in the proband's healthy sister; and bottom, guanine deletion at position 650 occurs at the end of a cytosine streak, a well-known hotspot in PKD. The variant results in a premature termination of transcription (p.R217Qfs*12). Left, family tree with various phenotypes indicated.</p></caption><graphic xlink:href="NG2019011056f2"/></fig></sec><sec sec-type="discussion" id="s2"><title>Discussion</title><p>Herein, we describe a patient with &#x0201c;galloping tongue&#x0201d; syndrome who was positive for the p.R217Q fs*12 mutation in the <italic>PRRT2</italic> gene. Galloping tongue is an uncommon movement disorder.<sup><xref rid="R1" ref-type="bibr">1</xref><xref ref-type="bibr" rid="R2">&#x02013;</xref><xref rid="R5" ref-type="bibr">5</xref></sup> The characteristics of these lingual movements have been variably described as transverse contractions, twisting, or undulating movements.<sup><xref rid="R2" ref-type="bibr">2</xref><xref ref-type="bibr" rid="R3">&#x02013;</xref><xref rid="R5" ref-type="bibr">5</xref></sup> Although these movements were present with the tongue at rest in most of the reported patients, in some cases the movements were also observed during sustained action.</p><p>Our patient had a mutation in the <italic>PRRT2</italic> gene known to be associated with PKD.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> However, she did not have the typical paroxysmal dyskinesias seen in PKD. Her abnormal movements were triggered by action but were not paroxysmal because they were present as long as the voluntary movement motion persisted, resembling an action dystonia. The topography of dyskinesia, isolated to the tongue, was also uncharacteristic of PKD. Still, we believe that the <italic>PRRT2</italic> mutation could be linked to the patient's movement disorder because it is action related and known causes of the disorder have been ruled out. Furthermore, the phenotype of <italic>PRRT2</italic> mutations is not limited to dystonia and chorea typical of PKD, but episodic ataxia and paroxysmal torticollis have also been described.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Seizures and migraine seem to be also part of the clinical spectrum.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p>The cause of the lingual movements in our patient remains uncertain. A functional movement disorder seemed unlikely because the movement disorder could not be disrupted, suppressed, or entrained with examiner maneuvers, which had no impact in the patient's life, and there was no obvious gain for the patient. The study of similar cases and additional <italic>PRRT2</italic> families will eventually clarify whether the &#x0201c;galloping tongue&#x0201d; syndrome is indeed a previously unrecognized manifestation of <italic>PRRT2</italic> mutations.</p></sec></body><back><sec sec-type="contribution"><title>Author contributions</title><p content-type="contribution">D. Vilas and E. Tolosa: drafting/revising the manuscript and conceptualization of the study. A. Marc&#x000e9;-Grau and A. Macaya: genetic analysis and revising the manuscript. J. Vall-Sol&#x000e9;: electrophysiologic study and revising the manuscript.</p></sec><sec sec-type="funding"><title>Study funding</title><p content-type="funding">No targeted funding reported.</p></sec><sec sec-type="disclosure"><title>Disclosure</title><p content-type="disclosure">Disclosures available: <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/6/e377/tab-article-info">Neurology.org/NG</ext-link>.</p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keane</surname><given-names>JR</given-names></name></person-group>
<article-title>Galloping tongue: post-traumatic, episodic, rhythmic movements</article-title>. <source>Neurology</source>
<year>1984</year>;<volume>34</volume>:<fpage>251</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">6538022</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saddichha</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Talukdar</surname><given-names>D</given-names></name></person-group>
<article-title>Serpentine tongue syndrome associated with risperidone long-acting injection treatment</article-title>. <source>J Clin Psychopharmacol</source>
<year>2014</year>;<volume>34</volume>:<fpage>657</fpage>&#x02013;<lpage>658</lpage>.<pub-id pub-id-type="pmid">25118081</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagappa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sinha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Saini</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bindu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Taly</surname><given-names>A</given-names></name></person-group>
<article-title>Undulating tongue in Wilson's disease</article-title>. <source>Ann Indian Acad Neurol</source>
<year>2014</year>;<volume>17</volume>:<fpage>225</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">25024581</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prashantha</surname><given-names>DK</given-names></name></person-group>
<article-title>Serpentingue tongue: a rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease</article-title>. <source>Parkinsonism Relat Disord</source>
<year>2009</year>;<volume>15</volume>:<fpage>718</fpage>&#x02013;<lpage>719</lpage>.<pub-id pub-id-type="pmid">19157953</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheehy</surname><given-names>SHC</given-names></name>, <name name-style="western"><surname>Lawrence</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Thevathasan</surname><given-names>AW</given-names></name></person-group>
<article-title>Serpentine tongue. A lingual dyskinesia</article-title>. <source>Neurology</source>
<year>2008</year>;<volume>70</volume>:<fpage>e87</fpage>.<pub-id pub-id-type="pmid">18490612</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#x000e9;neret</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Grabli</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Depienne</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>79</volume>:<fpage>170</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">22744660</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castelnovo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Renard</surname><given-names>D</given-names></name>, <name name-style="western"><surname>De Verdal</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Luc</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thouvenot</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Riant</surname><given-names>F</given-names></name></person-group>
<article-title>Progressive ataxia related to PRRT2 gene mutation</article-title>. <source>J Neurol Sci</source>
<year>2016</year>;<volume>367</volume>:<fpage>220</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">27423591</pub-id></mixed-citation></ref></ref-list></back></article>